Acadia Pharmaceuticals Reports Q3 Revenue of $342 Million and Raises DAYBUE Guidance
Acadia Pharmaceuticals (ACAD) reported strong third-quarter financial results, driven by record net sales for its product DAYBUE. Total revenues for the quarter reached $342 million, with NUPLAZID contributing $202 million and DAYBUE accounting for $140 million in net sales. Following these results, management has raised the revenue guidance for DAYBUE to a range of $505 million to $520 million. Furthermore, the company outlined an ambitious long-term target for DAYBUE, aiming for $700 million in sales by 2028.
Tickers: $ACAD
Topics: pharmaceutical sales quarterly earnings revenue growth